Ability Plus Therapy | A vaccine against diabetes, obesity, and intestinal diseases soon to be developed?
329
post-template-default,single,single-post,postid-329,single-format-standard,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,qode-theme-ver-14.3,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

A vaccine against diabetes, obesity, and intestinal diseases soon to be developed?

vaccine to help patients

A vaccine against diabetes, obesity, and intestinal diseases soon to be developed?

Researchers have developed a vaccine to fight chronic inflammatory diseases as well as “metabolic disorders” such as diabetes and obesity in animals. Explanations.

Discovery on a vaccine against chronic inflammatory bowel disease has been announced on the Inserm website.

Researchers at the Institut Cochin in France have succeeded in protecting animals against chronic inflammatory diseases such as Crohn’s disease and even diabetes or obesity.

Flagellin, responsible for the spread of bacteria, targeted.

Scientists have been interested in flagellin, a protein that promotes the mobility of bacteria within the intestinal flora, despite the mucus layer that is supposed to protect it. The researchers, therefore, stimulated the production of antibodies naturally present in this mucus to create an additional barrier against flagellin, which reduces the risk of inflammation.

Tests conducted on mice have shown that this “immunization against flagellin significantly protects animals against intestinal inflammation.”

Since excess flagellin is also responsible for other diseases such as diabetes or obesity, researchers also vaccinated mice “exposed to a high-fat diet.” As a result, treated animals have not become obese, unlike unvaccinated animals.

After successful animal trials, soon a vaccine for humans?

“This vaccination strategy is possible in humans since such microbiota abnormalities have been observed in patients with inflammatory and metabolic diseases. To this end, we are currently working on the way to administer flagellin locally to the intestinal mucosa,” said Benoît Chassaing, Inserm researcher and head of the team that conducted the research.

Scientists are now investigating the possibility of curing subjects who already have a chronic inflammatory disease or metabolic deregulations.

No Comments

Post A Comment